We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Loss of MicroRNA Induces Pro-Metastatic Changes in Pancreatic Cancer Cells

By LabMedica International staff writers
Posted on 14 Jun 2016
Reduced activity of a specific microRNA (miRNA) is apparent in chronically inflamed pancreatic tissue and in early stages of pancreatic cancer (pancreatic ductal adenocarcinoma or PDAC) even before tumor formation.

PDAC is characterized by very early metastasis, which has led some researchers to postulate that metastasis-associated changes may occur prior to actual tumor formation. More...
To confirm this hypothesis investigators at the German Cancer Research Center (Heidelberg, Germany) analyzed levels of miRNAs known to be linked to PDAC.

MicroRNAs are a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation.

The investigators reported in the May 23, 2016, online edition of the journal Cancer Research that they had identified the microRNA miR-192 as an epigenetically regulated suppressor gene with predictive value in PDAC. Levels of miR-192 were downregulated by promoter methylation in both PDAC and chronic pancreatitis (CP), a risk factor that leads to a 15-fold increase in the likelihood of contracting pancreatic cancer.

Functional studies in vitro and in mouse models of PDAC showed that overexpression of miR-192 was sufficient to reduce cell proliferation and invasion. Mechanistic analyses correlated changes in miR-192 promoter methylation and expression with epithelial-mesenchymal transition (EMT).

Cell proliferation and invasion were linked to altered expression of the miR-192 target gene SERPINE1, which encodes the protein plasminogen activator inhibitor-1 (PAI-1), an established regulator of these properties in PDAC cells. These results suggested that miR-192 downregulation established an invasive capacity in these pancreatic cells even before they transformed into cancer cells.

"We think that the cells often already have metastatic capacity before even transforming into cancer cells," said senior author Dr. Jörg Hoheisel, head of the division of functional genome analysis at the German Cancer Research Center. "To check this hypothesis, we searched the tumor cells for molecular changes that are indicative of the tendency to spread early. Our interpretation of these results is that epigenetic changes that occur already in inflamed pancreatic tissue lead to reduced production of miR-192. This means that the cells acquire the capacity of invasion and metastasis, which initially has no consequences. The actual transformation into cancer cells is caused by other, unrelated factors and can occur later. The result is cancer cells that are capable, from the very start, to invade surrounding tissue and spread metastases."

Related Links:
German Cancer Research Center


Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Capillary testing on the Atellica analyzers supports the most common laboratory testing needs (Photo courtesy of Siemens Healthineers)

Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers

Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more

Immunology

view channel
Image: New findings show unique pathogen‑directed antibody patterns are already present years ahead of a formal diagnosis of inflammatory bowel disease (Image Credit: iStock)

Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.